Gilead (GILD) Veklury Retains Activity Against Omicron Variant

Published on February 14, 2022

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Continue reading on website
Other news

Vulcan (VMC) 7.5% Dividend Hike Impresses Investors, Stock Up

February 14, 2022
Vulcan Materials (VMC) boosts quarterly dividend by 7.5%, given its strong performance and attractive underlying market fundamentals.

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

February 14, 2022
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.